Amended Current Report Filing (8-k/a)
May 18 2015 - 4:44PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 1, 2015
CORTEX
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
1-16467 |
|
33-0303583 |
(State
or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(I.R.S Employer
Identification No.) |
126
Valley Road, Suite C
Glen
Rock, New Jersey |
|
07452 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ] |
Written communications pursuant to
Rule 425 under the Securities Act (17 CFR 230.425) |
[ ] |
Soliciting material pursuant to Rule
14a-12 under the Exchange Act (17 CFR 240.14a-12) |
[ ] |
Pre-commencement communications pursuant
to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
[ ] |
Pre-commencement communications pursuant
to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Explanatory Note
On May 1, 2015, Cortex Pharmaceuticals, Inc. (the “Company”)
filed a Current Report on Form 8-K (the “Original Report”) that furnished, as Exhibit 99.1, a collection of slides
that the Company intended to use at its presentation at the New York BIO 25th Anniversary Conference (the “Conference”)
on May 4, 2015. The Company made its presentation at the Conference as scheduled.
Among other things, those slides referred
to a clinical study of the compound dronabinol, which was being conducted by the University of Illinois. Based on disclosures
by the University of Illinois, the Company expected the clinical study to be completed in the third quarter of 2015. After
the Conference, the University of Illinois disclosed that the expected completion
date for the clinical study had been changed to May 2016. Accordingly, attached as Exhibit 99.1 to this Current Report on
Form 8-K/A are revised slides (the “Revised Slides”) from the original exhibit that referenced the clinical
study, updated to reflect the new anticipated completion date of the clinical study. The full slide deck, with the Revised
Slides, will also be available on the Company’s web-site.
The remainder of the information provided with the Original Report
remains unchanged.
Item
9.01 Financial Statements and Exhibits
(d) Exhibits.
A list of exhibits that are furnished as part of this report is set forth in the Exhibit Index, which is presented
elsewhere in this document, and is incorporated herein by reference.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date: May 18, 2015 |
CORTEX PHARMACEUTICALS,
INC. |
|
(Registrant) |
|
By: |
/s/
ARNOLD S. LIPPA |
|
|
Arnold S. Lippa
President and Chief Executive Officer |
EXHIBIT
INDEX
Exhibit
Number |
|
Exhibit
Description |
|
|
|
99.1 |
|
Revised Slides amending certain slides furnished as Exhibit 99.1 to the Company’s Current Report on
Form 8-K filed May 1, 2015*
|
*Furnished
herewith.
Exhibit
99.1
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jun 2024 to Jul 2024
RespireRx Pharmaceuticals (CE) (USOTC:RSPI)
Historical Stock Chart
From Jul 2023 to Jul 2024